Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-1: Camizestrant vs Standard Endocrine Therapy in ER+/HER2- Early Breast Cancer
NCT05774951Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Primary completion
- Apr 2027
- Countries
- 39
01
Overview
Phase 3, randomised, open-label trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Invasive breast cancer-free survival up to 10 years. Started Mar 2023; status: recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05774951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774951.